• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Blue Shield of CA Offers COVID-19 Screener and Emergency Response Assistant

by Jasmine Pennic 03/18/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
6 Coronavirus (COVID-19) Considerations for Telehealth Providers

What You Should Know:

– Blue Shield of California offers COVID-19 Screener and Emergency Response Assistant (COVID-19 SERA) to help handle anticipated surge of COVID-19 patients.

– The COVID-19 SERA is developed by GYANT can be customized for each health system’s emergency response plan, and it is updated in real-time with latest guidelines from the Centers for Disease Control (CDC) and World Health Organization (WHO).


Blue Shield of California is offering a new digital tool to its network hospitals at no additional cost to help them triage the influx of patients seeking advice on coronavirus (COVID-19) or other medical care. This is the latest effort by the nonprofit health plan to support public health during the ongoing coronavirus crisis by helping hospitals be more effective and efficient in caring for their patients.

How COVID-19 SERA Works

The “COVID-19 Screener and Emergency Response Assistant” (COVID-19 SERA) is a tool that patients can access via Internet-connected smartphone, tablet or computer on a participating hospital’s website. COVID-19 SERA can be customized for each health system’s emergency response plan, and it is updated in real-time with latest guidelines from the Centers for Disease Control (CDC) and World Health Organization (WHO). The COVID-19 SERA is developed by GYANT, a San Francisco-based company that uses artificial intelligence to provide digital services that help people access appropriate care.

Patients would access COVID-19 SERA on a hospital’s websites, answer a few basic questions and based on their reply, they would be directed to the appropriate medical settings for their health situation. The idea is to point patients in the most appropriate care setting so hospitals can better manage inflow of patients.

The COVID-19 SERA service can be implemented on a hospital’s website within 48 hours. Blue Shield will cover the costs for its network hospitals to implement, update and be licensed to use COVID-19 SERA system for three months during the pandemic.

“The tool provides relief to hospitals’ overburdened call centers and front-desk resources. It can direct low-acuity cases to the appropriate medical settings and provide relevant information to patients affected by COVID-19 so that they can quickly receive medical care and help curb community transmission,” said Terry Gilliland, M.D., executive vice president, Healthcare Quality and Affordability at Blue Shield. “These are trying times for everyone and we believe this system can make a difference for hospitals as they do their best to provide medical care for patients.”


  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Coronavirus (COVID-19), Public Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |